Burning Rock Biotech Limited (BNR)
- Previous Close
0.7624 - Open
0.8000 - Bid 0.5250 x 200
- Ask 1.0400 x 200
- Day's Range
0.7700 - 0.8120 - 52 Week Range
0.5720 - 3.2500 - Volume
21,892 - Avg. Volume
48,920 - Market Cap (intraday)
82.14M - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9600 - Earnings Date May 28, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.95
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.
www.brbiotech.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BNR
Performance Overview: BNR
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNR
Valuation Measures
Market Cap
82.14M
Enterprise Value
-3.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.06
Price/Book (mrq)
0.69
Enterprise Value/Revenue
-0.01
Enterprise Value/EBITDA
0.00
Financial Highlights
Profitability and Income Statement
Profit Margin
-121.63%
Return on Assets (ttm)
-31.84%
Return on Equity (ttm)
-67.85%
Revenue (ttm)
537.44M
Net Income Avi to Common (ttm)
-653.69M
Diluted EPS (ttm)
-0.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
615.1M
Total Debt/Equity (mrq)
1.60%
Levered Free Cash Flow (ttm)
-194.87M
Research Analysis: BNR
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell